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In Brief
Antibodies enhance their functional
affinity by binding an antigen at multiple
sites. Because HIV-1 contains few
binding targets, the ability of antibodies
to neutralize the virus is greatly
decreased. Here, we develop a
statistical-mechanical model that
predicts the efficacy of synthetic
antibodies composed of two Fabs joined
together by DNA linkers of different
lengths and flexibilities. This model
predicts a synthetic antibody’s
neutralization potency based on its linker
composition, providing a framework to
guide the design of future multivalent
therapies.Inc.
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IgG antibodies increase their apparent affinities by
using both of their Fabs to simultaneously attach to
antigens. HIV-1 foils this strategy by having few,
and highly separated, Envelope (Env) spike targets
for antibodies, forcing most IgGs to bind monova-
lently. Here, we develop a statistical mechanics
model of synthetic diFabs joined by DNA linkers of
different lengths and flexibilities. This framework en-
ables us to translate the energetic and entropic ef-
fects of the linker into the neutralization potency of
a diFab. We demonstrate that the strongest neutral-
ization potencies are predicted to require a rigid
linker that optimally spans the distance between
two Fab binding sites on an Env trimer and that avid-
ity can be further boosted by incorporating more
Fabs into these constructs. These results inform
the design of multivalent anti-HIV-1 therapeutics
that utilize avidity effects to remain potent against
HIV-1 in the face of the rapid mutation of Env spikes.
INTRODUCTION
Despite decades of research since its discovery, human immu-
nodeficiency virus-1 (HIV-1) continues to threaten global public
health (UNAIDS, 2019). While there have been advances in our
understanding of the mechanisms of infection and the develop-
ment of preventative and therapeutic strategies, there remains
no cure for HIV-1 infection. Antiretroviral therapy with small
molecule drugs can control the progression of the virus, allowing
those infectedwith HIV-1 to live longer and healthier lives, but the
treatment includes detrimental side effects, and when discontin-
ued or not taken as prescribed, leads to viral rebound to pre-
treatment levels (Fauci, 2008). A major factor confounding the
development of a prophylactic vaccine is the rapid mutation of
HIV-1, which leads to the emergence of many new strains,
even within a single individual (Escolano et al., 2017). Thus,
most antibodies raised by the host immune system are strain-Cell Systems 9, 1–9, Dec
This is an open access article undspecific or neutralize only a subset of strains, leading to viral
escape from host antibodies.
Recent interest has focused upon the isolation of broadly
neutralizing immunoglobulin G (IgG) antibodies (bNAbs) from a
subset of HIV-1-infected individuals (McCoy and Burton,
2017). These antibodies bind to and block the functions of the
HIV-1 Envelope (Env) spike, the viral protein responsible for the
fusion of HIV-1 to the host cell (Klasse, 2012). The discovery
and characterization of HIV-1 bNAbs has brought new impetus
to the idea of passively delivering antibodies to protect against
or treat HIV-1 infection. bNAbs can prevent and treat infection
in animal models (Baba et al., 2000; Mascola et al., 2000; Hessell
et al., 2007, 2009; Klein et al., 2012, 2013, 2014) and exhibited
efficacy against HIV-1 in human trials (Caskey et al., 2015,
2017; Lynch et al., 2015; Schoofs et al., 2016). However, HIV-1
Env mutates to become resistant to any single bNAb, as even
the most potent NAbs developed in an infected individual nor-
mally fail to neutralize autologous circulating viral strains (Moore
et al., 2012; Liao et al., 2013; Wibmer et al., 2013; Doria-Rose
et al., 2014). As a result, antibodies that develop during HIV-1
infection appear to be unable to control the virus in an infected
individual.
We previously proposed that one mechanism by which HIV-1
evades antibodies more successfully than other viruses arises
from the low surface density of Env spikes that can be targeted
by neutralizing antibodies (Klein and Bjorkman, 2010; Galimidi
et al., 2015). Compared to viruses such as influenza A, dengue,
and hepatitis B, the density of Env spikes on the surface of
HIV-1 is about 2 orders of magnitude smaller (Klein and Bjork-
man, 2010). For example, influenza A hasz450 spikes per virion,
whereas each HIV-1 virion incorporates only 7–30 Env spikes
(average of 14) (Chertova et al., 2002; Zhu et al., 2003, 2006;
Liu et al., 2008; Klein and Bjorkman, 2010), even though both
influenza A and HIV-1 are enveloped viruses with z120-nm di-
ameters (Figure 1A). The HIV-1 spikes are the machinery by
which the virus binds its host receptor CD4 and coreceptor
CCR5/CXCR4 to mediate the fusion of the host and viral mem-
branes that allows its genome to enter target cells (Klasse,
2012). As a consequence of its small number of spikes, HIV-1
infection of target cells is inefficient; the transmission probabili-
ties for sexually acquired HIV-1 infection range from 0.4% to
1.4% (Patel et al., 2014). However, the reduced infectivity ofember 18, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Effects of Spike Density on IgG Binding
For a Figure360 author presentation of this figure, see https://doi.org/10.1016/j.cels.2019.09.007.
(A) Close spacing of surface spikes on influenza A allows bivalent binding of IgGs to adjacent spikes (red boxes). In contrast, HIV-1 has few spikes (14 on average)
spaced far apart, and because the HIV-1 spike architecture prohibits simultaneous binding of two Fabs to a single Env trimer, most IgGs bindmonvalently to HIV-
1 Envs (gold boxes). We investigated a synthetic diFab designed to bind bivalently to a single HIV-1 spike trimer (blue boxes).
(B) Schematics of a Fab, an IgG, a diFab composed of two Fabs joined together by d bp dsDNA, and two segments of s ssDNA bases, and a triFab made up of
three Fabs.
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bodies to control the virus, as the surface spikes serve as the
only targets for neutralizing antibodies that can block infection
of target cells (McCoy and Burton, 2017).
While the close spacing of spikes on typical viruses allows
IgG antibodies to bind bivalently to neighboring spikes (inter-
spike crosslinking) using both of their antigen-binding arms
(Fabs), most HIV-1 spikes are too far apart (typically over
20 nm separation) (Klein and Bjorkman, 2010) to permit inter-
spike crosslinking by IgGs whose antigen-binding sites are
separated by %15 nm (Saphire et al., 2001). Furthermore,
although each homotrimeric HIV-1 spike includes three binding
sites (epitopes) for an antibody, the architecture of HIV-1
Envs prohibits simultaneous binding of two Fabs within a single
IgG to the same Env (intra-spike crosslinking) (Klein, 2009;
Wang et al., 2017). We suggested that predominantly monova-
lent binding by anti-HIV-1 antibodies expands the range of Env
mutations permitting antibody evasion, since reagents capable
of bivalent binding through inter- or intra-spike crosslinking
would be less affected by Env mutations that reduce but do
not abrogate binding and thus may be more potent across mul-
tiple strains of HIV-1 (Klein and Bjorkman, 2010; Galimidi et al.,
2015). The hypothesis that HIV’s low spike numbers and low
densities contributes to the vulnerability of HIV-1 bNAbs to
spike mutations is supported by independent biochemical
and EM studies demonstrating that HIV-1 has an unusually
low number of spikes that are not clustered (Layne et al.,
1992; Chertova et al., 2002; Zhu et al., 2003, 2006; Liu et al.,2 Cell Systems 9, 1–9, December 18, 20192008), and that bivalent IgG forms of anti-HIV-1 NAbs are
only modestly more effective than monovalent Fabs, by
contrast to bivalent IgGs against other viruses, which can be
100s- to 1,000s-fold more potent than counterpart monovalent
Fabs (Klein, 2009; Klein and Bjorkman, 2010; Galimidi et al.,
2015; Wang et al., 2017).
An antibody’s neutralization potency against a virus is related
to its antigen-binding affinity, which is defined as the binding
strength between a Fab and its antigen (Eisen and Siskind,
1964) described by the equilibrium dissociation constant KD =
[Fab][Ag]/[Fab–Ag], where [Fab], [Ag], and [Fab–Ag] are the
concentrations of the antibody Fab, antigen, and the complex,
respectively (Azimzadeh and VanRegenmortel, 1990). In bivalent
molecules interacting with binding partners that are tethered to a
surface, the apparent affinity, or avidity, can be enhanced by
multivalent binding. Such multivalent interactions are seen in
many biological contexts including cell-cell communication, vi-
rus-host cell interactions, antibody-antigen interactions, and
Fc receptor interactions with antigen-antibody complexes (Kies-
sling and Lamanna, 2003). Avidity effects benefit these interac-
tions from both kinetic and thermodynamic standpoints. Binding
bivalently to tethered binding partners is advantageous kineti-
cally because if one arm dissociates, the likelihood of it finding
its binding partner is greater due to the constraint of being
tethered (Krishnamurthy et al., 2006). Avidity effects are also ad-
vantageous thermodynamically; whereas binding the first arm
results in losses of translational and rotational degrees of
freedom, the subsequent binding of the second arm incurs a
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In the context of an IgG with two antigen-binding Fabs, the
ability to bind bivalently to a virus is dependent on geometric fac-
tors such as the separation distances and orientations of teth-
ered epitopes either on adjacent spikes during inter-spike cross-
linking (Figure 1A, red box) or on individual spikes if intra-spike
crosslinking can occur (Figure 1A, blue box) (Karush, 1976).
Because the large distances between HIV-1 spikes makes in-
ter-spike crosslinking unlikely, in this work, we focus exclusively
on the latter mechanism of achieving bivalent binding. Although
IgGs are too small to intra-spike crosslink (Figure 1A, gold box)
(Klein, 2009; Wang et al., 2017), we previously engineered
larger reagents (homo- and hetero-diFabs) that were designed
to bind to a single Env, resulting in mean neutralization potency
increases over a panel of HIV-1 strains (Galimidi et al., 2015).
These diFab constructs were composed of two IgG Fabs joined
by different lengths of double-stranded DNA (dsDNA), which
served as both a rigid linker and a molecular ruler to probe the
conformations of HIV-1 Env on virions (Galimidi et al., 2015)
(Figure 1B). The dsDNA was flanked by two short single-
stranded DNA (ssDNA) segments, where the primary differ-
ences between the two types of DNA is that dsDNA is more rigid
and shorter ð0:34 nm =bpÞ than the more flexible and longer
ssDNA ð0:64 nm =baseÞ.
In this work, we develop a statistical mechanical model that
quantifies the potency of a diFab using its free energy of bind-
ing, which consists of two components. The first is the energy
gained when each Fab attaches to Env, a quantity that only de-
pends upon the identity of the Fab (the VH, VL, CH1, and CL seg-
ments in Figure 1B) and HIV-1 strain considered. The second
component of the free energy is the entropic cost of binding
either one or both Fabs to an Env, since a bound state restricts
the number of possible conformations of a diFab, decreasing
its likelihood. In our model, we enumerate the possible confor-
mations using a random walk model for the diFab linker (the
d bp dsDNA flanked by s bases ssDNA in Figure 1B).
Using our model, we can expand upon the earlier results of
these synthetic diFab constructs and theoretically analyze
whether changing the flexibility of the linker joining the two
Fabs could also enhance neutralization potency. This enables
us to compare a spectrum of possibilities from a rigid linker solely
comprising dsDNA to a fully flexible linker composed of only
ssDNA. We then generalize our model to a triFab design and
demonstrate that simultaneously binding to three Env epitopes
can greatly boost avidity. Insights from our synthetic constructs
can be adapted to antibody design in other systems, in which
length and rigidity of linkers in multivalent reagents must be
balanced to elicit the most effective response.
RESULTS
Estimating theParameters of diFabBinding fromCrystal
Structures
While HIV-1 Env fluctuates between multiple conformations, we
assume that a diFab neutralizes the virus by binding to one
specific state of Env at which the distance between the C-termini
of the two Fabs (where the DNA is joined) is defined to be llinker
(Figure 2A). For example, the predicted distance based onmodeling adjacent 3BNC60 Fabs on a low-resolution open
structure of an HIV-1 trimer (Merk and Subramaniam, 2013)
was z20 nm. More recently, we used the 3BNC117 Fab-
gp120 portion of a cryo-EM structure to measure the distance
between adjacent Fab CH1 C-termini in the closed conformation
of Env and then modeled a 3BNC60-gp120 protomer into three
recent cryo-EM structures of Env trimers in different conforma-
tions: an open Env bound by the b12 bNAb, in which the core-
ceptor binding sites on the V3 loops are not exposed (Ozorowski
et al., 2017); an open CD4-bound Env structure with exposed V3
loops (Ozorowski et al., 2017); and a partially open CD4-bound
Env, in which the gp120 subunits adopted positions mid-way
between closed and fully open (Wang et al., 2018). From these
structures, we measured distances of 15.8, 20.3, 20.4, and
20.1 nm between C-termini of Fab CH1 domains modeled onto
the closed, b12-bound open, CD4-bound open, and CD4-bound
partially open Env conformations, respectively. Based on these
values, we set llinker = 20 nm.
A further model parameter, lflex = 1 nm, shown in Figure 2Awas
included to account for the flexibility of the Fab. More precisely,
this parameter accounts for variations in the distance between
the C-termini of the two Fab CH1 domains to which the DNA
was attached due to the following factors: (1) the FabCH1-CL do-
mains can adopt different conformations with respect to VH-VL
(Stanfield et al., 2006) such that the locations of the CH1 C-termi-
nus could shift by up to z1 nm; (2) residues C-terminal to CH1
residue 217 were found to be disordered in the 3BNC60 Fab
structure (Scheid et al., 2011), thus the position of the CH1 resi-
due to which the DNA was attached (Cys233) is uncertain within
z1 nm; (3) the ssDNA is covalently linked to the CH1 residue
Cys233 using an amine-to-sulfhydryl crosslinker, which exerts
unknown effects on the length and the degree of flexibility be-
tween the ssDNA and Fab.
Relating Neutralization to the Probability that an HIV-1
Spike Is Bound
To model diFab efficacy in terms of the properties of the linker,
we first related the ability of a diFab to neutralize an HIV-1 virion
to the probability that an Env spike on the surface of HIV-1 will
be bound by an antibody. We assume that the spikes are suffi-
ciently far apart to preclude inter-spike crosslinking (Figure 1A,
red boxes) and focus exclusively on intra-spike crosslinking
between the three identical sites on the Env homotrimer (Fig-
ure 1A, blue boxes). We further assume that viral infectivity varies
linearly with the number of unbound Env, rising from zero (when
all spikes are bound by diFabs) to maximum infectivity (when all
spikes are unbound) as discussed in the STAR Methods section
‘‘% Neutralization and HIV-1 Env Binding Probability’’ (Klasse,
2007; Brandenberg et al., 2015).
Given these assumptions, the ability of a diFab to neutralize
HIV-1 is proportional to the probability that at least one of the
binding sites on an Env spike will be bound (see STAR Methods
section titled ‘‘% Neutralization and HIV-1 Env Binding Proba-
bility’’). For example, if each Env protein has a 75% chance to
be bound by a diFab, an average of 75% of the spikes on each
virion will be bound, and by the linearity assumption, the HIV-1
virions will be 75% neutralized. This enables us to relate the
experimentally determinable % neutralization for diFabs to the
theoretically tractable probability that a single Env spike willCell Systems 9, 1–9, December 18, 2019 3
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Figure 2. Modeling the Optimal Linker
Length for a diFab
(A) The energetic and entropic costs of mono-
valent binding depend upon the concentration [Ab]
and dissociation constant K
ð1Þ
D of a single Fab
binding. The boost in bivalent binding is dictated
by the geometric or avidity factors a (which is the
same for all diFabs) and n (which depends upon
the length of the dsDNA and ssDNA, the optimal
length llinker of the linker between two bound
Fabs, and the flexibility lflex between the CH1-CL
and VH-VL domains of a bound Fab). The ability to
neutralize is given by the sum of relative proba-
bilities for the monovalent and bivalent states
divided by the sum over all states.
(B) The boost a n of bivalently binding is computed
by treating the ssDNA as a random walk and the
dsDNA as a rigid rod (see STAR Methods section
titled ‘‘Number of Microstates in the Model
Including ssDNA’’). An optimal linker matches the
length of the dsDNA to the length between two
bound Fabs ðldsDNAzllinkerÞ, giving rise to many
configurations for the bivalently bound state and
increasing its likelihood.
(C and D) The relative probability that a diFab with
d bp dsDNA and s bases ssDNA is bivalently (p2)
versus monovalently (p1) bound (C) and the pre-
dicted IC50 values for these same constructs (D).
Parameters used were llinker = 20 nm, lflex = 1 nm,
a= 53 106, and K
ð1Þ
D = 100 nM.
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effects will allow an optimal diFab to bind more tightly to a
spike, increasing the binding probability and the neutralization
potency.
The Avidity of a diFab Is Dictated by Its Linker
Composition
To calculate the probability that any of the Fab binding sites on
an HIV-1 spike are occupied, we compute the free energy (the
energetic boost of the Fab-virus interaction and the entropic
penalty of confining the number of linker states) for the three
potential states of the spike, which represent a single diFab
bound to zero, one, or two binding sites (Figure 2A). The entropy
of the linker was characterized by treating the dsDNA as a 1D
rigid rod and the ssDNA as a random walk. The former assump-
tion is valid provided the dsDNA in each linker is less than the
150 bp persistence length of dsDNA (Brunet et al., 2015), a
reasonable restriction given that only 60 bp dsDNA are required
to span llinker = 20 nm. Free ssDNA is flexible with a persistence
length xssDNA = 1:5 nm (z2:3 bases) (TInland et al., 1997; Ambia-
Garrido et al., 2010) that we analyze using the ideal chain poly-
mer physics model (Doi and Edwards, 1986).
When a diFab transitions from the unbound state (with proba-
bility p0) to a monovalently bound state (with probability p1), it
loses translational and rotational entropy but gains favorable
binding energy (Phillips et al., 2013) leading to the relative
probability4 Cell Systems 9, 1–9, December 18, 2019p1
p0
=
½Ab
K
ð1Þ
D
; (Equation 1)
where [Ab] is the concentration of the diFab and K
ð1Þ
D is
the equilibrium dissociation constant of the first diFab arm bind-
ing to Env. K
ð1Þ
D can be experimentally determined as the IC50
(concentration of antibody capable of neutralizing 50% of the
virus) of a Fab neutralization profile, with a smaller IC50 signifying
a more potent antibody. We use the typical value K
ð1Þ
D = 100 nM
reported for a CD4-binding site bNAb dissociating from a solu-
ble, trimeric HIV-1 Env (Lyumkis et al., 2013). Importantly, the
transition from an unbound to a monovalently bound diFab is
independent of the amount of dsDNA and ssDNA in the diFab’s
linker.
We now turn to the transition from a monovalently bound
diFab to a bivalently bound diFab. The ability to simultaneously
bind two epitopes depends on the linker composition (the
quantity of dsDNA and ssDNA), since the distance llinker between
the C-termini of bivalently bound Fabs must be spanned by the
rigid dsDNA segments as well as the two flanking ssDNA strands
(Figure 2A). More precisely, we enumerate the configurations of
the ssDNA random walk and the dsDNA in the bivalently bound
state (Figure 2B), permitting us to compute the entropic cost of
bivalent binding (see STAR Methods section titled ‘‘Number of
Microstates in the Model Including ssDNA’’). Within this frame-
work, the probability of the bivalently bound state (p2) compared
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stant a that is independent of the linker composition and a term
nðldsDNA; lssDNAÞ that depends on the quantity of dsDNA and
ssDNA, namely,
p2
p1
= an
=
al2flex
llinker ldsDNA
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3xssDNA
8p3lssDNA
s
e

3ðl2linker + l2dsDNAÞ
8lssDNAxssDNA sinh

3llinkerldsDNA
4lssDNAxssDNA

(Equation 2)
where ldsDNA =dð0:34 nm =bpÞ and lssDNA = sð0:64 nm=baseÞ
represent the length of d dsDNA base pairs and s ssDNA bases
in the linker, respectively.
Equations 1 and 2, together with the normalization condition
p0 + p1 + p2 = 1, enable us to compute the probability that a di-
Fab will neutralize a virion,
p1 +p2 =
½Ab
K
ð1Þ
D
+
½Ab
K
ð1Þ
D
an
1+
½Ab
K
ð1Þ
D
+
½Ab
K
ð1Þ
D
an
; (Equation 3)
from which we can write the concentration of 50% inhibition,
ICdiFab50 =
K
ð1Þ
D
1+an
: (Equation 4)
The value of a= 53106 was calibrated from previous mea-
surements where a diFab with d=62 bp and s = 12 bases neutral-
ized HIV-1 approximately 100-fold better than the Fab alone
(Galimidi et al., 2015). Figure 2C compares the probability that
a diFab will be bivalently bound (p2) rather than monovalently
bound (p1) for different linkers. The model shows that bivalent
binding is most likely when llinkerzldsDNA, when the rigid dsDNA
approximately spans the length between the two bound Fabs.
This peak shifts leftwards with the root-mean-squared length
of the flexible ssDNA, demonstrating that ssDNA can make up
for dsDNA that is slightly too short or too long, provided the flex-
ibility of the ssDNA is taken into account. Figure 2D shows the
corresponding IC50s for these constructs. Although adding
more flexible ssDNA leads to a broader segment of dsDNA
lengths capable of enhanced neutralization, the optimal diFab
potency is achieved by including less ssDNA and maximizing
the rigidity of the linker.The diFab Model Allows Bivalent Binding Only When the
dsDNA Length Is Approximately Equal to the Length of
the Linker It Spans
To gain a qualitative understanding of our results, we examined
Equation 4 in two limits: near the optimal geometry ldsDNAz llinker
where the ability to bind bivalently is maximum and far from the
optimal limit when the diFab is too short or too long to permit
bivalent binding through intra-spike crosslinking.
Near the optimal geometry, HIV-1 neutralization occurs pre-
dominantly from the bivalently bound configuration rather than
the monovalent state, p2p1 = an[1. Hence, the system is well
approximated with each spike either being unbound or bivalentlybound, with the dissociation constant K
ð1Þ
D for a single Fab
boosted by the avidity factor an, namely,
ICdiFab50 z
K
ð1Þ
D
a n
: ðnear optimal geometryÞ (Equation 5)
If the potency of diFab 1 is IC
ð1Þ
50 and the potency of diFab 2with
a different linker is IC
ð2Þ
50 , the latter diFab’s potency will be shifted
relative to the former by the ratio of n factors, namely,
IC
ð2Þ
50
IC
ð1Þ
50
=
nð1Þ
nð2Þ
: (Equation 6)
In other words, the relative potency of both diFabs is determined
solely by the entropy, rather than the energy, of the linker when
bivalently bound.
In the opposite regime where the diFab linker is too small
(ldsDNA + lssDNA < llinker) or too large (ldsDNA  lssDNA > llinker), the
diFab loses the ability to bind bivalently and the IC50 attains a
constant value
IC50zK
ð1Þ
D ðfar from optimal geometryÞ (Equation 7)
shown as a black dashed line in Figure 2D.Avidity Is Further Enhanced Using a triFab that Binds
Three Env Sites
While the diFab constructs were inspired by two-armed IgG an-
tibodies, a triFab construct that could simultaneously bind to
three Env epitopes (Figure 1B) should exhibit even greater avidity
and hence neutralize HIV-1 more potently. For simplicity, we as-
sume that both dsDNA segments have the same length, as do all
ssDNA segments. As derived in the section titled ‘‘Generalizing
the Model to GappedFabs and TriFabs’’ of the STAR Methods,
the IC50 of such a construct is given by
ICtriFab50 =
K
ð1Þ
D
1+an+a2n2
: (Equation 8)
Figures 3A and 3B compare the neutralization potencies
across the design space of diFabs and triFabs, demonstrating
that joining three Fabs can result in IC50s far smaller than what
is possible for even the theoretically optimal diFab design.
The neutralization potency of a triFab near its optimal geome-
try (an[1) is dictated purely by the trivalently bound state,
ICtriFab50 z
K
ð1Þ
D
a2n2
: ðnear optimal geometryÞ (Equation 9)
Note that the boost in avidity in going from a Fab to a
diFab is equivalent to the boost between a diFab and triFab.
Since diFabs have been shown to achieve a 100–1,000
fold decrease in IC50 over a Fab, a triFab should be able to
achieve a 104–106-fold decrease in IC50 relative to the Fab,
providing a powerful framework with which to achieve very
high neutralization.
To put these results into perspective, potent IgGs commonly
have IC50 values on the order of 1 nM across a panel of HIV-1
viruses (Galimidi et al., 2015). While the effects of an escape
mutation can be highly heterogeneous (some shifting IC50 byCell Systems 9, 1–9, December 18, 2019 5
A B Figure 3. Neutralization Potency of
Different diFab and triFab Designs
(A and B) Predicted IC50s for (A) diFab or (B) triFab
constructs with linkers composed of d bp dsDNA
and s bases ssDNA segments. In both cases,
optimal neutralization occurs when the linker
matches the length between Fab binding sites
ðd = ð3 bp=nmÞllinker =60 bp Þ and has as little
ssDNA as possible. The triFab can achieve
significantly enhanced potency over the diFab
because of its additional avidity.
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100-fold [Falkowska et al., 2014; Dingens et al., 2017; Lee
et al., 2017]), escape mutations commonly increase IC50 by
roughly 10x. Assuming this rule of thumb, an optimal diFab can
withstand 2 escape mutations and remain as efficacious as a
potent IgG while an optimal triFab can tolerate 4 suchmutations.
To further enhance potency, more than three Fabs could be
joined together into a multiFab. By joining multiple types of
Fabs that bind to different epitopes (e.g., the broadly neutralizing
CD4-binding 3BNC117 with a V1V2-binding PG16), multiFabs
may enhance the potency of neutralization as well as help com-
bat HIV-1 heterogeneity as has been seen in combination influ-
enza antibodies (Laursen et al., 2018) and HIV-1 mosaic vac-
cines (Bricault et al., 2019).
An Optimal Linker Is Maximally Rigid and Perfectly
Spans the Distance between Env Epitopes
Counter to what might be intuitively expected, adding flexibility
to a linker by increasing the number of ssDNA bases need not
improve the diFab’s neutralization potential. This effect arises
because flexible ssDNA has a large number of degrees of
freedom that are constrained when the diFab bivalently binds,
leading to a larger entropic penalty (or smaller boost in avidity).
Indeed, the full diFab and triFab design space shown in Figure 3
demonstrates that an optimal construct is a perfectly rigid
linker composed of only dsDNA whose length matches the dis-
tance between HIV-1 epitopes (ldsDNAzllinker). However, we
caution that such diFabs may not operate optimally for both
experimental and theoretical reasons including: (1) the range of
dsDNA lengths that permit bivalent binding narrows as the
amount of ssDNA decrease, and in the extreme limit of a linker
with no ssDNA, being slightly too short or too long by as little
as a few base pairs may preclude bivalent binding; (2) charge
interactions between the dsDNA and either the Fab or Env may
disrupt diFab functionality; (3) a lack of sufficient flexibility at
the Fab-dsDNA junction may preclude bivalent binding; and (4)
in the limit of a rigid linker (ssDNA ( 10 bases) the ideal chain
model breaks down and the bending of ssDNA must be ac-
counted for (e.g., via the worm-like chain model), which may
result in higher IC50s than predicted by our model.
Because of these considerations, it is worthwhile to use a di-
Fab whose dsDNA length ldsDNA matches the distance between
Fab epitopes ðllinkerÞ found in crystal structures, and to flank6 Cell Systems 9, 1–9, December 18, 2019this dsDNA with short segments of
ssDNA (z10 bases) to buffer against un-
certainties in the measurements. As seenin Figure 3, such constructs lie within a wide basin with strong
neutralization potential. Of note, this strategy far surpasses a
purely flexible linker ðlssDNAzllinker; ldsDNA = 0Þ, which cannot
bivalently bind because of the large entropic cost. Other
methods of introducing flexibility, such as introducing ssDNA
breaks in the dsDNA linker, are also predicted to increase the
entropic cost of bivalent binding and hence increase the IC50
(see STAR Methods section titled ‘‘Generalizing the Model to
GappedFabs and TriFabs’’).
DISCUSSION
The low density of Env spikes on HIV-1 potentially enables the
virus to mitigate the host antibody response by hindering IgGs
from using both antigen-binding Fabs to bind bivalently, thereby
expanding the range of HIV-1 mutations permitting antibody
evasion (Klein and Bjorkman, 2010; Galimidi et al., 2015). Indeed,
a mutant simian immunodeficiency virus (SIV) with a higher
number of Env spikes reverted to its normal spike count of
z14 when propagated in non-human primate hosts (Zingler
and Littman, 1993). This suggests that while HIV-1 may be
more infectious with more Env trimers (Layne et al., 1990), the
immune system applies selective pressure that keeps the Env
spike count per virion low, presumably to prevent anti-HIV-1
IgGs from utilizing avidity effects to counter the lower intrinsic
Fab-Env affinities that result from rapid mutation of Env. Anti-
body isotypes, such as dimeric IgA or pentameric IgM, have
increased valencies (four and ten Fabs, respectively) compared
to the two Fabs of an IgG, thus allowing for increased avidity
effects during antibody binding to a pathogen. However, most
of the neutralizing activity in the sera of HIV-1-positive individuals
is attributed to IgGs (Tomaras et al., 2008; Scheid et al., 2009),
and converting an anti-HIV-1 IgG antibody to an IgA or IgM
hasminimal effects on potency in standard neutralization assays
(Wolbank et al., 2003; Kunert et al., 2004), possibly because
there are so few Env spaced sufficiently far apart that these
other antibody classes are also forced to bind monovalently.
Bivalent binding to single Env trimer (intra-spike crosslinking)
is another way to utilize avidity effects to counteract the low
spike density of HIV-1. Although the architecture of Env trimers
prohibits this mode of binding for conventional, host-derived
IgGs (Klein, 2009; Wang et al., 2017), we analyzed how synthetic
diFabs (Fabs from a neutralizing anti-HIV-1 IgG joined by a linker
Please cite this article in press as: Einav et al., Harnessing Avidity: Quantifying the Entropic and Energetic Effects of Linker Length and Rigidity for
Multivalent Binding of Antibodies to HIV-1, Cell Systems (2019), https://doi.org/10.1016/j.cels.2019.09.007containing rigid dsDNA flanked by flexible ssDNA shown in Fig-
ure 1B) could be designed to achieve optimal intra-spike
crosslinking.
HIV-1 Env trimers adopt multiple conformations on virions
(Liu et al., 2008; Munro et al., 2014) and in the soluble native-
like forms used for structural studies (Ward and Wilson, 2017).
For example, binding of the host CD4 receptor induces outward
displacements of the three Env gp120 subunits, resulting in an
open conformation in which the coreceptor binding sites on
the trimer apex V3 loops are exposed (Harris et al., 2011;
Wang et al., 2016, 2018; Ozorowski et al., 2017) and that rear-
ranges further upon coreceptor binding and subsequent
membrane fusion. We measured the distances between adja-
cent 3BNC117 epitopes in a new cryo-EM structure (Lee et al.,
2017) and estimated the average position of the C-terminal
CH1 domain residue to which the DNA of a 3BNC117 diFab
would be covalently attached (Stanfield et al., 2006). Based on
these measurements, we assumed that a diFab neutralized
HIV-1 when the linker spans a length llinker = 20 nm. We further
assumed that the Fab CH1-CL domains can stretch relative to
the VH-VL domains by lflex = 1 nm (see Figure 2A). Lastly, we
considered a Fab whose ability to dissociation (as given by the
midpoint of a neutralization assay) equals to K
ð1Þ
D = 100 nM.
Each of these values can be readily adapted to other HIV-1
strains and Fabs.
With these parameters in hand, we developed a statistical
mechanics-based model to predict the neutralization of a diFab
whose linker is composed of d base pairs dsDNA and s bases
ssDNA (Figure 1B), enabling us to tune both the length and
rigidity of the linker. By assuming that (i) each homotrimeric
spike is unable to help infect a host cell when any one of its three
epitopes are bound by Fab and (ii) that the infectivity of a virion
varies linearly with the number of unbound Env, we showed
that the neutralization of a virion is proportional to the probability
that any single Env protein is bound by a Fab (see STAR
Methods section titled ‘‘% Neutralization and HIV-1 Env Binding
Probability’’). This framework enabled us to translate the linker-
dependent entropy and energy of binding to an HIV-1 Env trimer
into the predicted neutralization potency for each diFab.
It is worthwhile to point out several factors that the model
neglects. First, the model does not consider potential, but pre-
sumably rare, diFab binding between adjacent Env trimers. Sec-
ond, our model assumed that the % neutralization of HIV-1 de-
creases linearly with the number of unbound Env trimers. While
such a linear relationship was observed when less than half of
HIV-1 spikes were bound (Layne et al., 1990), it may break
down if, for example, at least 2–3 unbound Env trimers are
needed to infect a cell. We also assumed that each virion had
exactly 14 spikes, neglecting the relatively small observed spike
number variations (Chertova et al., 2002; Zhu et al., 2003, 2006;
Liu et al., 2008). However, relaxing these assumptions minimally
changes the neutralization curves (which may become slightly
sharper, as shown in the STAR Methods section titled ‘‘%
Neutralization and HIV-1 Env Binding Probability’’), suggesting
that our results are robust and should apply to more general de-
scriptions of HIV-1 neutralization.
We determined that an optimal linker will maximize its rigidity,
trading flexible ssDNA for rigid dsDNA. The larger flexibility of
ssDNA implies that there will be a higher entropic penalty forbivalently binding, thereby resulting in a worse (larger) IC50.
This general statement applies to all forms of increased flexibility
including: (1) trading dsDNA for an equivalent length of ssDNA,
(2) adding ssDNA without decreasing the length of dsDNA, or
(3) introducing ssDNA gaps in the dsDNA (see STAR Methods
section titled ‘‘Generalizing the Model to GappedFabs and
TriFabs’’).
In addition to tuning the length of dsDNA and ssDNA in
the linker, another biologically inspired approach to further in-
crease avidity is to construct multiFabs that target more than
two epitopes. As has been seen in other biological systems
(Kitov and Bundle, 2003; Liese and Netz, 2015; Yan et al.,
2018), higher valencies can elicit tighter binding. Hence, a triFab
that allows three Fabs to simultaneously bind to an HIV-1 Env
trimer is predicted to have a lower IC50 than an optimal diFab;
indeed, our model predicts that the boost from avidity of
an optimal diFab over a Fab is equivalent to the boost of an
optimal triFab over an optimal diFab, and hence we expect
that triFabs should be able to achieve IC50s 10
4–106 fold smaller
than Fabs. MultiFabs that link together Fabs targeting different
epitopes (e.g., the broadly neutralizing CD4-binding site anti-
body 3BNC117 and the V2-binding PG16 antibody) (Bricault
et al., 2019) could better combat the heterogeneity of HIV-1
strains, providing guidance for constructing optimal anti-HIV-1
therapeutics that remain potent against HIV-1 in the face of the
Env mutations arising during HIV-1 replication.STAR+METHODS
Detailed methods are provided in the online version of this paper
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METHOD DETAILS
% Neutralization and HIV-1 Env Binding Probability
In this section, we determine the relationship between the experimentally measurable% neutralization and the probability pbound (de-
noted by p1 +p2 in the main text) that a trimeric Env spike will have a Fab bound to any of its three identical epitopes.
We begin by defining the typical % neutralization assay. We then analyze a linear model of HIV-1 infectivity discussed in the main
text where the ability of the virus to infect a target cell is proportional to the number of Env spikes not bound by an antibody. We also
discuss alternative models of infectivity, in which someminimal number of active spikes is required for a virion to infect a cell, finding
that this model yields nearly identical predictions to the linear model.
Lastly, we investigate the importance of the experimentally-measured distribution of Env spikes on HIV. We start by assuming that
each virion has the same number of spikes (given by the mean of the measured distribution) and then relax this assumption to char-
acterize how infectivity changes when the number of Env spikes per virion is drawn from the full distribution.
Defining % Neutralization
In previous work, in vitro neutralization assays were carried out in 96 well plates, each well containing 250 TCID50 and 25,000 cells
that emit bioluminescence upon infection by the Pseudovirus as described (Montefiori, 2005). Antibodies and other potential inhib-
itors of neutralization are in vast excess over Pseudovirus and cells in these assays (e.g., 1 nM of antibody corresponds to 1011 mol-
ecules/well). Upon infection, the cells emit light via a luciferase reporter as shown in Figure S1A.We define the percent of Pseudovirus
neutralized as the fold-change in bioluminescence in the presence and absence of an inhibitor, namely,
% neutralization= 100
ðviral control cell controlÞ  ðbioluminescence  cell controlÞ
viral control cell control ; (Equation 10)
where bioluminescence is a measure of the light emitted in a well containing the pseudoviruses, cells, and antibodies; viral control is
an assay using only cells and viruses (no antibodies) so that the cells emitmaximal bioluminescence; and cell control is an assay using
only cells (no viruses or antibodies) (Figure S1A).
The relative infectivity of a virion is defined as 100 ð% neutralizationÞ, which equals 100%when no antibodies are present and 0%
at saturating antibody concentrations where the binding sites on each HIV-1 spike are occupied.
From these assays, we define the equilibrium dissociation constant K
ð1Þ
D characterizing the binding of the first diFab arm to HIV-1
Env (which is equivalent to the dissociation constant between a diFab with only one functional arm) as the midpoint of the neutral-
ization curve. In this work, we chose the typical value K
ð1Þ
D = 100 nM from previous experiments.
A Linear Model of HIV-1 Infectivity
Wenow consider the linearmodel for HIV-1 infectivity used in themain text, which is predicated on the following assumptions: (i) each
virus has the same number N= 14 of Env trimers (or spikes), taken to be the mean of the experimentally measured distribution, (ii)
each spike is active (able to help HIV-1 infect a target cell) if and only if none of its three subunits are bound by an antibody, and
(iii) the relative infectivity of a virion is linearly proportional to its number of active spikes. Taken together, these assumptions imply
that a virus with 7 active Env trimers shown on the left in Figure S1B will be half as infective as a completely unbound virus with 14
active trimers shown on the right.
The first assumption simplifies our analysis; below we relax this assumption and show that it minimally alters the % neutralization
curves. The second assumption, that a spike is inactivated if at least one of its Fab sites is bound, is supported by experimental and
computational studies (23). The third assumption has been observed when less than half the HIV-1 spikes are bound (27), but relative
infectivity decreases faster than a linear model when more than half of the spikes are bound. In the following section, we relax this
assumption and show that it minimally alters the% neutralization curves by making them slightly sharper. Taken together, these cal-
culations demonstrate that our results are robust to the details of HIV-1 neutralization.
With these assumptions, a virion with n active spikes out of N = 14 spikes total will have n=N the relative infectivity of a completely
unbound virus, and hence the % neutralization is given by the expectation 1001C1 n=ND, which equals 0% in the absence of anti-
bodies when all spikes are active (n = N) and equals 100% at saturating antibody concentrations when all spikes are inactive (n = 0).e1 Cell Systems 9, 1–9.e1–e7, December 18, 2019
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N
n

ð1 pboundÞnpNnbound and hence % neutralization is given by the weighted average of having n unbound spikes,
% neutralization = 100
PN
n= 0
pðnÞ

1 n
N

= 100
PN
n= 0
0@N
n
1Að1 pboundÞnpNnbound1 nN
= 100 100
N
XN
n= 0
0@N
n
1Að1 pboundÞnpNnboundn
= 100 100
N
Nð1 pboundÞ
= 100 pbound;
(Equation 11)
where in the fourth equality we used the average value of the binomial distribution. Therefore, the statistical mechanical model we
develop to characterize the probability that a diFab is bound to Env also describes the ability of that diFab to neutralize a virion.
Equation 11 demonstrates that the exact number of spikes on an HIV-1 virion does not matter, implying that our framework will
apply even in the face of the natural variation in spike density (Chertova et al., 2002; Zhu et al., 2003, 2006; Liu et al., 2008; Klein
and Bjorkman, 2010). In particular, although the average distance between HIV-1 spikes is too large to inter-spike crosslink, the
random positioning of these spikes on any virion may bring some subset of them sufficiently close to allow bivalent binding. Preclud-
ing the unlikely case where all spikes are precisely positioned to all be simultaneously crosslinked, Equation 11 guarantees that the
remaining N spikes outside the subset (and hence viral neutralization) will conform to our model.
Imposing a Hard Threshold for HIV-1 Infectivity
We now relax the third assumption stated above that relative infectivity is proportional to the number of active (i.e., unbound) HIV-1
spikes (Figure S1C, Linear). Instead, we posit that some minimum number of spikes must be active for a virion to be able to infect a
target cell. This minimum number has been predicted to be between 1-3 active spikes (Brandenberg et al., 2017). Hence, we inves-
tigate two additional models where at least 3 of the HIV-1 spikes must be active for a virion to infect a target cell. In the first model
(Figure S1C, Linear with a Hard Threshold), the relative infectivity increases linearly (and hence the % neutralization decreases line-
arly) with the number of active spikes >3, while in the secondmodel (Figure S1C,Hard Threshold) we impose a pure threshold so that
a virus is maximally infective provided at least 3 spikes are active.
For each model, we can alter the avidity factor a to match the midpoints of each curve (a = 1:53 106, 106, or 73106 for the linear
model, the linear model with a hard threshold, or the hard threshold model, respectively), since this parameter would ordinarily be
inferred from a neuralization assay. As shown in Figure S1C, the linear model with a hard threshold is nearly identical to the linear
model without this threshold, except that its % neutralization rises to 100% at lower antibody concentrations because it only needs
to neutralize N 2 spikes to disable each virion. The hard-threshold model is sharper than the linear model, with the transition be-
tween no neutralization and full neutralization occurring when there are enough antibodies to bind N 2 spikes. Having noted these
slight discrepancies, using any of thesemodels wouldminimally affect our results, and hencewe chose to proceed using the simplest
linear response.
% Neutralization Is Unchanged If the Number of env Spikes Varies between Virions
In this section, we relax the first assumption stated above and consider the number of spikes N on each virion to be drawn from a
distribution ranging from 7-30 spikes per virion with an average of 14 (Chertova et al., 2002; Zhu et al., 2003, 2006; Liu et al.,
2008; Klein and Bjorkman, 2010). We assume that the relative infectivity of a virus increases with each additional spike (with a
maximum value attained by a virus with Nmax = 30 active spikes). The calculation for % neutralization follows analogously to Equa-
tion 11, except that the% neutralization of a virus with n active spikes is proportional to 1 n=Nmax and that% neutralization must be
averaged over all possible values of N drawn from its distribution, namely,
% neutralization f
* PN
n= 0
0@N
n
1Að1 pboundÞnpNnbound1 nNmax
+
= 1 CND
Nmax
ð1 pboundÞ;
(Equation 12)
In experimental measurements, % neutralization is always stretched to run from 0% to 100%; and if we apply this same stretching to
Equation 12, we recover the result that % neutralization= 100pbound as in Equation 11.Cell Systems 9, 1–9.e1–e7, December 18, 2019 e2
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no longer hold. Yet given that HIV-1 has so few spikes, it may turn out that each spike increases the relative infectivity of the virus by
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Number of Microstates in the Model including ssDNA
In this section, we enumerate the number of microstates associated with the three conformations of an HIV-1 Env spike – the un-
bound (U0), singly bound (U1), and bivalently bound states (U2) – shown in Figure S2. Our goal is to quantify the small fraction of linker
configurations that enable a diFab to span the distance llinker and bivalently bind.
The relative probability of each Env state is proportional to its Boltzmann weight, ebðEjTSjÞ = UjebEj , where b = 1=kBT, Ej is the
energy of state j, T is the temperature (37C), kB = Boltzmann’s constant, S= kB logUj is the entropy, and Uj is the number of micro-
states of state j. Thus, the relative probabilities of the bivalent and monovalent states satisfy
p2
p1
=
U2
U1
ebðE2E1Þ (Equation 13)
where pj, Ej, and Uj represent the probability, energy, number of microstates when j Fabs are bound to an Env, respectively.
The number of configurations U1 for a monovalently-bound diFab is proportional to the number of degrees of freedom available
when one Fab is bound to its epitope and the second Fab is unbound but tethered to the first by DNA. More precisely, the different
conformations arise from the rotation of the rigid dsDNA together with the small ssDNAmotions. Since the associated entropy of this
motion increases slowly with size, U1 is effectively constant across all diFabs regardless of their linker composition. Similarly, since
we assume that all diFabs are made up of the same Fab (e.g., all made using 3BNC117), the binding energy E2  E1 gained when the
second Fab in a diFab binds to the HIV-1 spike is the same across all constructs. Thus, the only parameter in Equation 13 that varies
across diFabs with different linkers is the number of states U2 of a bivalently bound linker, which we now proceed to compute.
The Ideal Chain Model for ssDNA and dsDNA
We model the dsDNA as a 1D rigid rod and the ssDNA as a random walk with a step size given by its Kuhn length
bssDNA = 2xssDNA = 3 nm= 4:7 bases (TInland et al., 1997; Ambia-Garrido et al., 2010). As in the main text, ldsDNA denotes the total
length of dsDNA while lssDNA denote the length of each of the two ssDNA segments.
Intuitively, because random walks tend to wander around their starting point, the optimal diFab will match its dsDNA length to the
distance between the C-termini of two bound Fabs (ldsDNAzllinker), to lose as little entropy as possibly when transitioning from a
monovalently-bound to a bivalently-bound state. As shown in Figure 2B of the main text, a diFab that is too short (ldsDNA  llinker)
or too long (ldsDNA[llinker) must stretch its ssDNA outwards or inwards to bivalently bind, thereby severely limiting the number of
possible configurations in the doubly bound state. In the extreme limits where llinker>ldsDNA + 2lssDNA + lflex or llinker<ldsDNA 
2lssDNA  lflex, bivalent binding is impossible (recall that lflex is the length by which the Fab can stretch as shown in Figure 2A). We
will now make these statements precise by computing the probability that a linker configuration will permit a diFab to be bivalently
bound.
Computing the Probability of Bivalent Binding
Wefirst turn our attention to the number ofmicrostates of a bivalently bound linker ignoring the flexibility of the Fab shown in Figure 3A
(i.e., in the lflex = 0 limit). Our goal will be to compute the probability pðldsDNA; lssDNA; llinkerÞ that the two ssDNA random walks and the
dsDNA segment will span the appropriate distance llinker necessary for the two Fabs to bivalently bind and then use this probability to
count the number of microstates available for bivalent binding. In the last section, we consider the case where lflexs0.
As shown in Figure S3A, each ssDNA random walk is composed of bn = lssDNA=bssDNA segments (where the notation distinguishes
this variable from n in Equation 2) with Kuhn length bssDNA = 2xssDNA. The ssDNA and dsDNA in the linker must together span a fixed
l
.
linker, where the direction andmagnitude of this vector is determined by the geometry of the Env spike’s epitopes. We now compute
the probability that two ssDNA random walks sandwiched between a dsDNA rigid rod of size l
.
dsDNA spans l
.
linker. We proceed by
considering four increasingly complex cases Case 1 : l
.
dsDNA = 0
.
; l
.
linker = 0
.
.
We begin by analyzing the special case of a diFabwith an infinitesimally small dsDNA segment ( l
.
dsDNA = 0
.
) binding to two epitopes
that essentially lie on top of one another ( l
.
linker = 0
.
). In other words, the constraint l
.
dsDNA = 0
.
implies that both ssDNA random walks
start off at the same location whereas l
.
linker = 0
.
specifies that both randomwalks must end at the same location. This setup is shown
in Figure S3Bwhere the two randomwalks begin in the green square and end upwithin a small distance of each other represented by
the gray cube.
Rather than analyzing the first random walk (with steps s
.
1ð1Þ, s.1ð2Þ, and s.1ð3Þ) and the second random walk (with steps s.2ð1Þ,
s
.
2ð2Þ, and s.2ð3Þ) individually, we construct an effective random walk that traverses along one of the original walks and back along
the other ( s
.
effðjÞ= s.1ðjÞ for 1%j%3 and s.effðjÞ=  s.2ðj  3Þ for 4%j%6). This mapping is bijective, whichmeans that every instance of
the original randomwalks will correspond to a unique effective randomwalk and vice versa. Hence, the two original randomwalks will
end at the same point if and only if the effective randomwalk ends near the origin. Therefore, pð0; lssDNA; 0Þ equals the probability that
this effective random walk returns to the origin.e3 Cell Systems 9, 1–9.e1–e7, December 18, 2019
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.
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P

r
.
dV =dV
 
3
2pbnb2ssDNA
!3
2
e
 3r2
2bnb2
ssDNA : (Equation 14)
Since each segment of the random walk can point in any direction, this probability only depends on the magnitude of r
.
and
decreases exponentially with its distance from the origin. Note that Pð r.Þ is a probability density that upon multiplication by an infin-
itesimal volume dV denotes the probability of a random walk ending between r
.
and r
.
+ d r
.
.
The probability that the effective random walk, formed by combining the two ssDNA random walks, will end up inside an infinites-
imal volume dV around the origin is given by Equation 14 with bn/2bn and r./0.. Therefore, the fraction of bivalent binding
configurations relative to monovalent binding configurations for two ssDNA random walks that start and end at the same location
( l
.
dsDNA = 0
.
; l
.
linker = 0
.
) is given by
pð0; lssDNA;0Þ=P

0
.
dV =dV
 
3
4pbnb2ssDNA
!3
2
: (Equation 15)
Thus far, our calculation has been in terms of the probability Pð0.ÞdV . To convert this result into the number of microstates
(and thereby compute the entropy), define U to be the number of microstates of each independent ssDNA segment (the 2bn ssDNA
segments are all assumed to rotate freely in the ideal chain model), the total number of microstates for the bivalent binding config-
urations is given byU
2n
pð0;lssDNA;0Þ. We note that thisUwill ultimately be subsumed into the a factor in Equation 2 Case 2 : l
.
dsDNA =
0
.
; l
.
linkers0
.
.
We next consider the case where two ssDNA random chains with no interspersed dsDNA ( l
.
dsDNA = 0
.
) must end up at a displace-
ment l
.
linker. As shown in Figure S3C, the two ssDNA randomwalks are equivalent to the probability that a single randomwalk with 2bn
steps will finish at l
.
linker. Therefore, the fraction of random walk configurations that allow bivalent binding when l
.
dsDNA = 0
.
and
l
.
linkers0
.
is given by Equation 14 with bn/2bn and r./ l.linker, namely,
pð0; lssDNA; llinkerÞ=Pð l
.
linkerÞdV =dV
 
3
4pbnb2ssDNA
!3
2
e
 3 l
2
linker
4bnb2
ssDNA : (Equation 16)
As in Case 1, the total number of bivalent microstates is then given by U
2n
pð0; lssDNA; llinkerÞ Case 3 : l
.
dsDNAs0
.
; l
.
linker = 0
.
.
We next turn to a diFab whose two ssDNA ends must end at the same point ( l
.
linker = 0
.
) but whose linker contains dsDNA
( l
.
dsDNAs0
.
) that can point in any direction. Analogous to the ssDNA segments, we assume the dsDNA hasUmicrostates (discretized
by solid angle so that the length of the dsDNA segment does not affect this number).
As shown in Figure S3D, the second randomwalk must end in a spherical shell of radius ldsDNA surrounding the endpoint of the first
random walk (note that we neglect the negligible width of the DNA double helix). We combine the two random walks into a single
random walk with 2bn steps by reversing the direction of the second random walk (pink) and translating it by  l.dsDNA so that it starts
where the first random walk (purple) ends. Hence, the diFab can bind bivalently if and only if this effective random walk ends at a
distance ldsDNA from the origin.
Since Pð r.Þ is radially symmetric about the origin, the number of microstates for any particular orientation of the dsDNA will be
U
2bn
Pð l.dsDNAÞdV and the total number of microstates considering all dsDNA orientations will be U2bn +1Pð l.dsDNAÞdV . However,
in preparation for Case 4 below, it is instructive to compute the probability over linker states as the average over all dsDNA
orientations,
pðldsDNA; lssDNA;0Þ = dV
4pl2dsDNA
Z
x
.˛Bð 0.;ldsDNAÞ
Pðx.Þd2 x.
= PðldsDNAÞdV
= dV
 
3
4pbnb2ssDNA
!3
2
e
 3l
2
dsDNA
4bnb2
ssDNA
;
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orientations of the ssDNA and theU orientations of the dsDNA. The similarity between Equations 16 and 17 reflect
the symmetry between the dsDNA and the linker length in the system Case 4 : l
.
dsDNAs0
.
; l
.
linkers0
.
.
Finally, we turn to the case of a general diFab where the two ssDNA random walks are separated by a displacement l
.
dsDNA of
dsDNA and must end with displacement l
.
linker from each other. As above, we transform these two random walks into a single effec-
tive random walk with 2bn steps that must finish in a spherical shell centered at l.linker with radius ldsDNA (Figure S3E). Analogous to
Case 3 above, the fraction of states of the dsDNA and ssDNA linker that allow bivalent binding is given by
pðldsDNA; lssDNA; llinkerÞ= dV
4pl2dsDNA
Z
x
.˛Bð l.linker ;ldsDNAÞ
Pð x.Þ d2 x. (Equation 18)
where Bð z.; rÞ represents the spherical shell of radius r centered at z. and Pð x.Þ is given by Equation 14 with bn/2bn. This final integral
is straightforward to evaluated analytically (see Data S1), yielding
pðldsDNA; lssDNA; llinkerÞ= dV
llinkerldsDNA
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3
16 p3 bnb2ssDNA
s
e

3ðl2linker + l2dsDNAÞ
4bnb2
ssDNA sinh
 
3 llinkerldsDNA
2 bnb2ssDNA
!
: (Equation 19)
This leads to Equation 2 with bssDNA = 2xssDNA, bn = lssDNA=2xssDNA, and with the constant dV dropped (since it can be absorbed
into a). Therefore, the number of configurations for the bivalently bound diFab linker is given by U2 = U
2bn +1
pðldsDNA; lssDNA; llinkerÞ.
Note that pðldsDNA; lssDNA; llinkerÞ has no free parameters and is dictated purely by the geometry of each diFab. Furthermore, the fac-
tor pðldsDNA; lssDNA; llinkerÞ is the only term that varies between diFabs, whereas all remaining parameters (e.g., Kð1ÞD ; E2  E1) are the
same across all constructs. Hence, it is the solely the loss of entropy contained in pðldsDNA; lssDNA; llinkerÞ that determines how
much better one diFab will be than another. Lastly, we point out that Equation 19 is symmetric upon interchanging ldsDNA and
llinker, since every state of the ssDNA in a bivalently bound diFab with ldsDNA dsDNA and receptor binding sites spaced llinker apart
would also enabled bivalent binding (with the locations of the dsDNA and the receptor interchanged) of a diFab with a length llinker
of dsDNA binding to a receptor with binding sites spaced ldsDNA apart.
The Number of Bivalent versus Monovalent Microstates for the Linker
In this section, we now consider the flexibility lflex of the diFab and compute the full expressions for the number of microstatesU1 and
U2 of the monovalently bound and bivalently-bound Env spike shown in Figure S3A. (We note that the number of microstates for the
unbound state U0 need not be computed explicitly because the ratio of entropy and energy between the unbound and monovalently
bound states are quantified by K
ð1Þ
D in Equation 1).
The number of microstates of the monovalently bound state is given by
U1 =U
2bn + 1
; (Equation 20)
where, as above, U denotes the microstates of each segment in the linker (the 2bn ssDNA segments and the 1 dsDNA segment are all
assumed to rotate freely in the ideal chain model). Note that this simple model neglects all interactions between the DNA, Fab, and
Env including self-intersections.
When lflex = 0, the multiplicity of the bivalently bound state was found above to be U
2bn +1
pðldsDNA; lssDNA; llinkerÞ where llinker repre-
sents the distance spanned by the linker. If we approximate the direction of flexibility of the Fabs and the line joining the Fabs’
C-termini to be colinear, the number of bivalent microstates is given by
U2 =
U
2bn +1
ðDlÞ2
Z lflex
2
lflex
2
Z lflex
2
lflex
2
pðldsDNA; lssDNA; llinker + x2  x1Þdx2dx1
z
U
2bn +1
l2flex
ðDlÞ2 pðldsDNA; lssDNA; llinkerÞ;
(Equation 21)
In the first equality, Dl represents a length scale that discretizes the flexibility imparted by the Fabs into the number of microstates. In
the second equality, we assumed lflex  llinker (since lflexz20 nm and llinkerz1 nm) so that llinker + x2  x1zllinker in the integrand.
Substituting Equations 19 and 21 into Equation 13, the relative probability of the bivalent and monovalent states takes the form
p2
p1
=
ebðE2E1ÞdV
ðDlÞ2bssDNA
l2flex
llinker ldsDNA
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3
16 p3 bn
r
e

3ðl2linker + l2dsDNAÞ
4bnb2
ssDNA sinh
 
3llinker ldsDNA
2bnb2ssDNA
!
h anðldsDNA; lssDNAÞ
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ðDlÞ2bssDNA
containing the constants that are independent of the diFab and Env and
nðldsDNA; lssDNAÞ to be the remaining geometry-dependent terms as per Equation 2. Using the normalization condition p0 + p1 + p2 =
1, we find that the % neutralization of HIV-1 for a diFab linked together by dsDNA and ssDNA is given by
p1 +p2 =
½Ab
K
ð1Þ
D
+
½Ab
K
ð1Þ
D
anðldsDNA; lssDNAÞ
1+
½Ab
K
ð1Þ
D
+
½Ab
K
ð1Þ
D
anðldsDNA; lssDNAÞ
: (Equation 23)
As a final aside, we note that the ideal chain model is valid when there are at least 3 segments in the randomwalk (Figure S4), which
requires 3bssDNAz14 bases of ssDNA in the diFab. Constructs whose ssDNA has at least this many bases should be well character-
ized by our model, whereas diFabs with less ssDNA would require the more complicated worm-like chain model.
Generalizing the Model to GappedFabs and TriFabs
In this section, we discuss how the model of diFab neutralization (Equation 4) can be generalized to account for either gappedFabs
with ssDNA breaks within the dsDNA segment or triFabs that combine three Fabs to achieve greater avidity effects.
GappedFabs Represent a Random Walk of dsDNA
Here, we consider the effects of placing small ssDNA breaks within the dsDNA as shown in Figure S5A. For simplicity, we restrict our
analysis to linkers composed of a middle segment with d2 bp dsDNA, surrounded by n1 segments of d1 bp dsDNA (each connected
by short ssDNA segments; n1 = 2 in the three gappedFabs shown in Figure S5A), and flanked by s bases ssDNA on either side. This
structure enables us to consider both the two outer ssDNA segments and the n1 dsDNA segments as randomwalks about the single
dsDNA segment of length d2 (and it is straightforward to generalize to arbitrary gappedFab designs). In doing so, we assume the short
ssDNA segments connecting the dsDNA act as free hinges with negligible lengths.
Equation 18 shows that in the case n1 = 0 where the linker must span the distance l
.
linker, the combined ssDNA random walk (2n
segments of length bssDNA) starting at the originmust end on a sphere of radius ldsDNA around l
.
linker. When n1>0, the combined ssDNA
random walk ends at the arbitrary point z
.
, and the dsDNA random walk must then start at z
.
and end on a sphere of radius ld2 =
d2ð0:34 nm =bpÞ around l
.
linker, representing the length of the d2 segment. Using the probability density Equation 14 for a random
walk, the probability that the linker in a gappedFab will bivalently bind is given by
pgapðldsDNA; lssDNA; llinkerÞ=
Z
x
.˛Bð l.linker ;ld2Þ
Z
z
.˛R3
PssDNAð z.ÞPdsDNAðx. z.Þd3 z.d3 x. (Equation 24)
where
PssDNAð z.Þ=
 
3
2pb2ssDNAð2nÞ
!3
2
e
 3z2
2b2
ssDNA
ð2nÞ (Equation 25)
represents the probability that the endpoint of the ssDNA random walk starting at the origin will end at z
.
,
PdsDNAðx. z.Þ=
 
3
2pl2d1n1
!3
2
e
3j x
. z.j2
2l2
d1
n1 (Equation 26)
denotes the probability that the endpoint of the dsDNA randomwalk starting at z
.
will end at x
.
, and ld1 = d1ð0:34 nm =bpÞ. Replacing
p/pgap and U
2n
/U
2n+n1 in Equation 21 yields the desired number of microstates for the bivalent configuration.
Figure S6 shows how the potency of the previously constructed diFab (d=62, s=12) gets worse (larger IC50) as the dsDNA segment
is broken up into bn pieces of equal length (n1 = bn 1, d1 = d2 = 62bn , s = 12). Since the bn segments of dsDNA will be much more
confined when the diFab is bivalently bound relative to the monovalent configuration, the entropic penalty of bivalent binding quickly
increases with the number of segments leading to lower potency.
TriFabs Exhibit Greater Avidity Than diFabs
Previously, we showed that the diFab with (d=62, s=12) has an IC50 that is 100-fold smaller than its one-armed Fab counterpart (Ga-
limidi et al., 2015). This raises the question of whether a construct with additional Fabs could further reduce the IC50. Here, we outline
how our model can be extended to consider a linear triFab (shown in Figure 1B), and this calculation can be readily extended to the
alternate triFab designs in Figure S5B. The calculation below predicts that the optimal triFab will be 100-fold more potent than the
optimal diFab, providing a method to leverage the knowledge of the HIV-1 Envelope spike we derived from our synthetic diFabs to
engineer even more potent reagents.
We model the ssDNA segments with s bases as random walks and neglect both the self-intersection of these random walks as
well as intersections with the Env spike, though we note that these effects may bemore prominent in a triFab than in a diFab. Further-
more, we neglect the combinatorics characterizing which binding arm attaches to an Env binding site (e.g., there are

3
1

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
3
2

ways to bind bivalently, although in the linear triFab the simultaneous binding of nearest neighbor arms will
be different from the binding of the two arms furthest apart; and

3
3

ways to bind trivalently) as well as the details of these config-
urations (e.g., there are six possible configurations of binding the three triFab arms to the three Env epitopes).
With these assumptions, the Boltzmann statistical weights for the triFab (analogous to those in Figure 2A for the diFab) are 1, ½Ab
K
ð1Þ
D
,
½Ab
K
ð1Þ
D
an, and ½Ab
K
ð1Þ
D
a2n2 for the stateswith 0, 1, 2, and 3 Fab arms bound, respectively. Analogous to Equation 23, the probability of binding
(and hence neutralizing) a spike is given by
p1 +p2 +p3 =
½Ab
K
ð1Þ
D
+
½Ab
K
ð1Þ
D
an+
½Ab
K
ð1Þ
D
a2n2
1+
½Ab
K
ð1Þ
D
+
½Ab
K
ð1Þ
D
an+
½Ab
K
ð1Þ
D
a2n2
(Equation 27)
with an IC50 given by
ICtriFab50 =
K
ð1Þ
D
1+an+a2n2
: (Equation 28)
As described in the main text, this implies that the boost in avidity in going from an optimal diFab to an optimal triFab is equal to the
boost in going from a Fab to an optimal diFab.
DATA AND CODE AVAILABILITY
The Supplemental Information includes six figures as well as a Mathematica notebook that reproduces the calculations and plots in
this manuscript. All files can be found in the online version of this article.e7 Cell Systems 9, 1–9.e1–e7, December 18, 2019
